Exelixis | EXEL - Operating Expenses


Exelixis reported $359.47M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Amgen USD 4.78B 1.12B Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Bayer EUR 9.88B 452M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Cytokinetics USD 200.58M 4.46M Mar/2026
Eisai JPY 215.74B 15.84B Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Exelixis USD 359.47M 3.28M Mar/2026
Genmab DKK 798M 235M Dec/2025
Glaxosmithkline GBP 9.17B 1.4B Dec/2025
Incyte USD 5.62B 4.5B Mar/2026
Ionis Pharmaceuticals USD 364M 54M Mar/2026
MacroGenics USD 21.2M 32.13M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Moderna USD 1.78B 242M Mar/2026
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sanofi EUR 10.71B 1.32B Dec/2025
Takeda JPY 1.11T 85.29B Mar/2026
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
Xencor USD 82.38M 513K Mar/2026